Evidence map›Paper›PMID 40545725›Full record

ArticleClinical and translational medicine2025

Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study.

Francesca Basso-Valentina, Vincenzo Canzonieri, Rossella De Cecio, Laura Arenare, Domenica Lorusso, Sabrina Chiara Cecere, Eliana Pivetta, Daniela Russo, Annabella Di Mauro, Grazia Artioli and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Francesca Basso-ValentinaMolecular Oncology Unit, Department of Research and Diagnostic, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.ORCID https://orcid.org/0000-0002-4340-182X
Vincenzo CanzonieriPathology Unit, Department of Research and Diagnostic, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.
Rossella De CecioPathology Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy.
Laura ArenareClinical Trials Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy.
Domenica LorussoDepartment of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli and Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Sabrina Chiara CecereUro-Gynecological Medical Oncology, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy.
Eliana PivettaMolecular Oncology Unit, Department of Research and Diagnostic, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.
Daniela RussoMicroenvironment Molecular Targets Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy.
Annabella Di MauroPathology Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy.
Grazia ArtioliOncologia Medica, ULSS 2 Marca Trevigiana, Treviso, Italy.
Anna SpinaMicroenvironment Molecular Targets Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy.
Carmine De AngelisDepartment of Medical Oncology, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Daniela CalifanoMicroenvironment Molecular Targets Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy.
Saverio CinieriMedical Oncology Division and Breast Unit, Senatore Antonio Perrino Hospital, ASL Brindisi, Brindisi, Italy.
Giosuè ScognamiglioScientific Directorate, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy.
Vanda SalutariDepartment of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli and Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Paolo ChiodiniDepartment of Mental Health and Public Medicine, Section of Statistics, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy.
Francesco PerronePathology Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy.
Sandro PignataUro-Gynecological Medical Oncology, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy.
Gustavo BaldassarreMolecular Oncology Unit, Department of Research and Diagnostic, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.

Funding

Alleanza Contro il Cancro RCR-2022-23682287Associazione Italiana per la Ricerca sul Cancro IG 25932Associazione Italiana per la Ricerca sul Cancro IG 26253Associazione Italiana per la Ricerca sul Cancro Italy Post-Doc Fellowship 29639Associazione Italiana per la Ricerca sul Cancro Italy Post-Doc Fellowship 31335Ministero della Salute CO-2018-12367051Ministero della Salute PNRR-MAD-2022-12375663Ministero della Salute RicercacorrenteL1andL3/13Ministero dell'Università e della Ricerca ARS01_00568
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40545725
PMCPMC12183328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.